Biotech Values

[dewophile]

idix
"The most intriguing revelation from today’s CC, IMO, was that ribavirin can compete with a nucleoside analog during the first phosphorylation step, and hence eliminating this step in vivo can allow the nuke to perform better when given with ribavirin."

i didn't catch the cc - that is interesting


"I don’t think anything other than safety can be ascertained from 3-day monotherapy studies"

if efficacy can't be ascertained then how does this serve as a proof of concept?
i agree efficacy is difficult to determine in a 3 day study, and extrapolating before steady state may not be valid - but it did strike me that at approx 3 days (i eyeballed the valopicitabine curve from a presentation) 184 did about what the first generation achieved at the highest dose (again this may not be a fair comparison, but it's all we have to go on interms of efficacy at this point..)